- Home
- MEIP vs IBO Comparison
MEIP vs IBO Comparison
Compare MEIP & IBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- IBO
- Stock Information
- Founded
- MEIP 2000
- IBO 2018
- Country
- MEIP United States
- IBO United States
- Employees
- MEIP N/A
- IBO N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- IBO
- Sector
- MEIP Health Care
- IBO
- Exchange
- MEIP Nasdaq
- IBO NYSE
- Market Cap
- MEIP 19.5M
- IBO 16.5M
- IPO Year
- MEIP 2003
- IBO 2024
- Fundamental
- Price
- MEIP $2.78
- IBO $2.61
- Analyst Decision
- MEIP Hold
- IBO
- Analyst Count
- MEIP 2
- IBO 0
- Target Price
- MEIP $7.00
- IBO N/A
- AVG Volume (30 Days)
- MEIP 53.1K
- IBO 63.5K
- Earning Date
- MEIP 11-12-2024
- IBO 11-12-2024
- Dividend Yield
- MEIP N/A
- IBO N/A
- EPS Growth
- MEIP N/A
- IBO N/A
- EPS
- MEIP N/A
- IBO 0.01
- Revenue
- MEIP N/A
- IBO N/A
- Revenue This Year
- MEIP N/A
- IBO N/A
- Revenue Next Year
- MEIP $300.00
- IBO N/A
- P/E Ratio
- MEIP N/A
- IBO $216.02
- Revenue Growth
- MEIP 33.76
- IBO N/A
- 52 Week Low
- MEIP $2.61
- IBO $1.22
- 52 Week High
- MEIP $6.91
- IBO $3.25
- Technical
- Relative Strength Index (RSI)
- MEIP 36.75
- IBO N/A
- Support Level
- MEIP $2.76
- IBO N/A
- Resistance Level
- MEIP $2.91
- IBO N/A
- Average True Range (ATR)
- MEIP 0.11
- IBO 0.00
- MACD
- MEIP -0.04
- IBO 0.00
- Stochastic Oscillator
- MEIP 5.13
- IBO 0.00
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.